Alvotech Resubmits U.S. Applications for Biosimilars Targeting J&J's Simponi and Regeneron's Eylea

Alvotech (ALVO) announced the resubmission of its U.S. marketing applications for biosimilars AVT05 and AVT06, targeting Johnson & Johnson’s (JNJ) Simponi and Regeneron Pharmaceuticals’ (REGN) Eylea. The announcement led to a spike in Alvotech's stock price.

By Dulan Lokuwithana, SA News Editor · Seeking Alpha · June 4, 2026, 18:34 UTC

Tickers: $JNJ $REGN

Read the full article at Seeking Alpha

More World news

Stellantis CEO Warns of Multi-Billion Euro Impact from Chip Shortages and Raw Material Costs Seeking Alpha · November 12, 2026, 16:44 UTC
UBS Upgrades Rivian to Buy Rating Amid R2 Potential Motley Fool · November 12, 2026, 16:45 UTC
Stifel Downgrades EVgo to Hold Amid Weakening Growth Outlook Seeking Alpha · November 12, 2026, 16:41 UTC
Rowan Digital Infrastructure Secures Over $1.5 Billion in New Financing Seeking Alpha · November 12, 2026, 16:42 UTC
CAE Reports Q2 2027 Results with Increased EPS Guidance and Strong Defense Growth Motley Fool · November 12, 2026, 16:39 UTC
Alvotech Reports Q3 2026 Financial Results Amid Manufacturing Recovery Motley Fool · November 12, 2026, 16:39 UTC
Jacobs Solutions Declares Quarterly Dividend of $0.36 Per Share Seeking Alpha · November 12, 2026, 16:39 UTC
SOLV Energy Raises Revenue Guidance Following Record Q3 Project Execution Seeking Alpha · November 12, 2026, 16:40 UTC
LiveWorld Reports Q3 Revenue of $2.98 Million and GAAP EPS of -$0.01 Seeking Alpha · November 12, 2026, 16:37 UTC
Jensen Huang Resigns as Nvidia CEO Amid Allegations of Chinese Espionage The Verge · November 12, 2026, 16:30 UTC